TWOCELLS

TWOCELLS is a bio-venture company established in 2003 by spinning out of Hiroshima University, based on a pre-venture project "Team for regenerative medicine of osteocartilaginous tissues" founded and run by JST (Japan Science and Technology Agency) in 2000 to 2003. The company's mission is to bring regenerative medicine to the world, and by particularly targeting MSC, which is a type of somatic stem cells, it is engaging in the development of cellular medicine with MSC, peri-MSC culturing technique and a system for regenerative medicine. TWOCELLS has developed "gMSC®1, a Regenerative Cellular Medicine for Chondrogenesis in the Knee" (for which TOWCELLS has licensed Chugai), and "Serum-free medium STK® series for MSC (for research)" (which is distributed by DS Pharma Biomedical Co., Ltd.). TWOCELLS received the supports from JST (Japan Science and Technology Agency), NEDO (New Energy and Industrial Technology Development Organization), AMED (Japan Agency for Medical Research and Development), METI (Ministry of Economy, Trade and Industry), Hiroshima Prefecture and Hiroshima city and could push our business forward. The revenue in 2016 of TWOCELLS totalled 800 million yen and the ordinary income was 160 million yen.